siderations are similar to those discussed for AD except that the combination of parkinsonism and dementia is a more difficult management problem, and because dementia is usually a late complication of PD, it may signify a shorter lifespan than for patients with either uncomplicated PD or AD.
There is ongoing development of more highly selective neuroleptic agents with less toxicity than clozapine. One recent report suggested that selective serotonin receptor blockade may offer one such strategy. See the section on Movement Disorders.
Was this article helpful?